Lynn Anne Bristol

Array ( [id] => 16238282 [patent_doc_number] => 20200255516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => TIGIT ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/651764 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18128873 [patent_doc_number] => 11555072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => A33 antibody compositions and methods of using the same in radioimmunotherapy [patent_app_type] => utility [patent_app_number] => 16/649617 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 40 [patent_no_of_words] => 43409 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172712 [patent_doc_number] => 11572409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Antibodies having specificity for BTN2 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/648886 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17202 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778063 [patent_doc_number] => 20190002570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/133579 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16133579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778097 [patent_doc_number] => 20190002587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => MONOCLONAL ANTI-TK1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/132047 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16132047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187554 [patent_doc_number] => 11578123 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Stable and soluble antibodies inhibiting TNFa [patent_app_type] => utility [patent_app_number] => 16/128691 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 19608 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 442 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283781 [patent_doc_number] => 20200277383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/644585 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16644585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072335 [patent_doc_number] => 20190085055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/122417 [patent_app_country] => US [patent_app_date] => 2018-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16122417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963087 [patent_doc_number] => 20200165295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHOD FOR PURIFYING ANTI-IL-6 RECEPTOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/635134 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605967 [patent_doc_number] => 10906959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Therapeutic biologic for treatment of hepatocellular carcinoma [patent_app_type] => utility [patent_app_number] => 16/116644 [patent_app_country] => US [patent_app_date] => 2018-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 27 [patent_no_of_words] => 16365 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16116644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17742622 [patent_doc_number] => 11390679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-19 [patent_title] => Anti-LAG-3 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/639827 [patent_app_country] => US [patent_app_date] => 2018-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 21872 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156623 [patent_doc_number] => 20200216544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1 [patent_app_type] => utility [patent_app_number] => 16/638559 [patent_app_country] => US [patent_app_date] => 2018-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17938439 [patent_doc_number] => 11472880 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Humanized antibodies for CD3 [patent_app_type] => utility [patent_app_number] => 16/635303 [patent_app_country] => US [patent_app_date] => 2018-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 29914 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17756270 [patent_doc_number] => 11396554 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Bispecific antibody for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 16/058398 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 9271 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16058398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16800212 [patent_doc_number] => 10995133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Method for producing antibody [patent_app_type] => utility [patent_app_number] => 16/052970 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 8392 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16052970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901895 [patent_doc_number] => 20190040152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => BCMA Monoclonal Antibody-Drug Conjugate [patent_app_type] => utility [patent_app_number] => 16/050944 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16050944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072403 [patent_doc_number] => 20190085089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => ANTI-Ly6E ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/050936 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16050936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574947 [patent_doc_number] => 20180339022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS [patent_app_type] => utility [patent_app_number] => 16/044561 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16044561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997870 [patent_doc_number] => 11498964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Antibody constructs for CDH19 and CD3 [patent_app_type] => utility [patent_app_number] => 16/040927 [patent_app_country] => US [patent_app_date] => 2018-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 21 [patent_no_of_words] => 74272 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2707 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572923 [patent_doc_number] => 10894836 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Antibody Fc mutants with ablated effector functions [patent_app_type] => utility [patent_app_number] => 16/037304 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 10578 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037304 [rel_patent_id] =>[rel_patent_doc_number] =>)